Jazz Pharmaceuticals experienced a dramatic financial deterioration, swinging from $560.1M net income to a $356.1M loss while current liabilities more than doubled to $2.2B.
This represents a complete reversal of profitability alongside a concerning liquidity position, as the company burned through $1B in cash while liabilities surged. The magnitude of these changes suggests either a major one-time event, significant operational challenges, or potential accounting adjustments that warrant immediate investor attention and management explanation.
Jazz's financial profile deteriorated dramatically across all key metrics, with the company swinging from profitable operations ($716.6M operating income) to substantial losses (-$430.2M), while simultaneously experiencing a massive increase in current liabilities that more than doubled to $2.2B. The company's cash position weakened significantly, declining 42% to $1.4B, while operating expenses surged with R&D up 32% and SG&A up 31%, creating a perfect storm of declining liquidity and profitability. This financial reversal, combined with the liability surge and cash burn, signals either a major restructuring, significant legal settlement, or fundamental operational challenges that require immediate clarification from management.
Net income declined 163.6% — review whether driven by operations, interest costs, or non-recurring items.
Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.
Current liabilities surged 115.9% — significant near-term obligations; verify ability to meet short-term debt.
Interest expense declined — debt repayment or refinancing at lower rates improving earnings quality.
Buyback activity reduced 59.9% — capital being redeployed elsewhere or cash conservation underway.
Capital expenditure jumped 54.3% — major investment cycle underway; assess returns on deployment.
Cash declined 42.3% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.
R&D investment increased 32.3% — signals commitment to future product development, though near-term margin impact.
SG&A up 30.6% — significant increase in sales or administrative costs, monitor impact on operating leverage.
Receivables grew 15.9% — monitor days sales outstanding for collection efficiency.
See what changed in your portfolio's filings
500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.
Try Tracenotes free →